The Influx Healthtech IPO is set to open on June 18, 2025, marking a significant step for the Mumbai-based contract manufacturer specializing in healthcare products. With a price band of ₹91 to ₹96 per share, the company aims to raise approximately ₹58.57 crore through a combination of fresh issue and offer for sale. Influx Healthtech operates three advanced manufacturing facilities in Thane, Maharashtra, certified to international standards, and serves major clients across dietary supplements, cosmetics, ayurvedic products, veterinary nutrition, and homecare.
₹20
₹96
₹132.50
Expert Opinions
The Influx Healthtech IPO enters the market amid cautious optimism as investor sentiment toward SME sector offerings remains selective, with many recent IPOs facing mixed listing performances. The company’s core strengths lie in its robust manufacturing infrastructure—three advanced, GMP-compliant facilities in Thane—and a diversified client base across dietary supplements, cosmetics, ayurvedic products, veterinary nutrition, and homecare. Its rapid revenue and profit growth since inception in 2020 further underscore operational execution and market adaptability. However, risks include dependence on contract manufacturing, regulatory compliance, and potential margin pressures from raw material costs or competition.
Valuation metrics for Influx Healthtech IPO in FY 2025 are compelling, with a Return on Equity (ROE) of 36.98%, Return on Capital Employed (ROCE) of 49.17%, and Net Asset Value (NAV) per share of ₹19.91, indicating efficient capital utilization and strong profitability. For long-term investors, Influx Healthtech’s scalable business model, advanced manufacturing capabilities, and healthy financials position it well for sustained growth, provided it navigates sector-specific risks and maintains its growth trajectory.
Investor Considerations
Investors considering the Influx Healthtech IPO should first assess its strong company fundamentals, highlighted by consistent revenue and profit growth, efficient capital utilization, and robust return metrics such as a recent Return on Equity (ROE) of 36.98% and ROCE of 49.17%. The sector outlook is positive, given the expanding demand for contract manufacturing in healthcare, dietary supplements, and wellness products, driven by rising health awareness and regulatory support. The Influx Healthtech IPO’s FY 2025 valuation metrics—Price to Book Value of 7.62, PAT margin of 12.75%, and a negligible debt/equity ratio of 0.01—reflect a premium for growth potential but also warrant caution regarding valuation multiples.
Growth prospects are supported by scalable operations, an expanding product portfolio, and international certifications, positioning the company for further market penetration. Key risk factors include reliance on contract manufacturing, regulatory changes, and potential margin pressure from raw material costs. For short-term investors, market sentiment and listing gains may be attractive, while long-term investors may benefit from the company’s strong fundamentals and sector tailwinds, provided risks are managed effectively.
| Date | GMP | Trend |
|---|---|---|
| 24 Jun 2025 11.08 | ₹20 | Down |
| 23 Jun 2025 10.38 | ₹22 | --- |
| 21 Jun 2025 10.51 | ₹22 | --- |
| 20 Jun 2025 19.50 | ₹22 | --- |
FAQs
The Grey Market Premium showed low accuracy in predicting Influx Healthtech IPO’s listing performance. With a final GMP of ₹20, it projected a 20.83% premium over the issue price of ₹96. However, the stock delivered a massive listing gain of 38.02% at ₹132.50. This resulted in a prediction error of 17.19%, where the GMP correctly indicated a positive debut but significantly underestimated the actual gain, demonstrating limited reliability as a predictor in this case.
Influx Healthtech IPO Current GMP is ₹20.
Influx Healthtech IPO Expected Returns is 20.83%.
Influx Healthtech IPO estimated listing price is ₹113.